European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Jaypirca, pirtobrutinib, Date of authorisation: 30/10/2023, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 15 September 2026 - 15:44

Human medicines European public assessment report (EPAR): Jaypirca, pirtobrutinib, Date of authorisation: 30/10/2023, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Trodelvy, sacituzumab govitecan, Date of authorisation: 22/11/2021, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 15 September 2026 - 15:30

Human medicines European public assessment report (EPAR): Trodelvy, sacituzumab govitecan, Date of authorisation: 22/11/2021, Revision: 8, Status: Authorised

Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, European Medicines Agency, Amsterdam, the Netherlands, from 15 September 2026, 09:30 (CEST) to 15 September 2026, 13:30 (CEST)

Submitted by Anonymous (not verified) on 15 September 2026 - 15:21

Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, European Medicines Agency, Amsterdam, the Netherlands, from 15 September 2026, 09:30 (CEST) to 15 September 2026, 13:30 (CEST)

Human medicines European public assessment report (EPAR): Bekemv, eculizumab, Date of authorisation: 19/04/2023, Revision: 7, Status: Authorised

Submitted by Anonymous (not verified) on 15 September 2026 - 14:55

Human medicines European public assessment report (EPAR): Bekemv, eculizumab, Date of authorisation: 19/04/2023, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Camcevi, leuprorelin, Date of authorisation: 24/05/2022, Revision: 7, Status: Authorised

Submitted by Anonymous (not verified) on 15 September 2026 - 14:45

Human medicines European public assessment report (EPAR): Camcevi, leuprorelin, Date of authorisation: 24/05/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): DuoPlavin, clopidogrel,acetylsalicylic acid, Date of authorisation: 14/03/2010, Revision: 32, Status: Authorised

Submitted by Anonymous (not verified) on 15 September 2026 - 14:10

Human medicines European public assessment report (EPAR): DuoPlavin, clopidogrel,acetylsalicylic acid, Date of authorisation: 14/03/2010, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Enwylma, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 15 September 2026 - 14:00

Human medicines European public assessment report (EPAR): Enwylma, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness